Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-951 in Combination with Paclitaxel for Advanced or Metastatic Breast Cancer
2008-002109-38Phase 2Completed
- Sponsor
- AVEO Oncology
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivozanib in breast cancer, sponsored by AVEO Oncology. Primary endpoints: Safety and tolerability of AV-951 plus paclitaxel, Maximum tolerated dose (MTD) of AV-951 in combination with paclitaxel and 1 more. Started Jul 2008; status: completed.
02
Drugs
tivozanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-002109-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002109-38.